Prostate International最新文献

{"title":"The addition of peri-operative gentamicin with ciprofloxacin reduces infection and sepsis rates post transrectal prostate biopsy","authors":"Arjun Guduguntla ,&nbsp;Andrew Xu ,&nbsp;Kieran W. Benn ,&nbsp;Prassannah Satasivam","doi":"10.1016/j.prnil.2024.11.006","DOIUrl":"10.1016/j.prnil.2024.11.006","url":null,"abstract":"<div><h3>Objective</h3><div>Despite the advent of transperineal (TP) biopsy and reduced risk of infective complications, transrectal ultrasound-guided (TRUS) prostate biopsy is still widely performed worldwide. The accepted prophylactic antibiotic is usually a single agent oral fluoroquinolone; however, this approach is beset by growing antibiotic resistance. The aim of this study was to assess whether the addition of intravenous gentamicin (2 mg/kg or at least 160 mg), immediately prior to biopsy, in conjunction with routine ciprofloxacin prophylaxis, reduced infection and sepsis rates post TRUS biopsy.</div></div><div><h3>Method</h3><div>Six hundred fifty-eight patients underwent TRUS biopsy at our center from 2017 to 2022, of whom 648 had data sufficient for analysis. We performed a retrospective analysis focusing on patient demographics (age, BMI, diabetes status), biopsy parameters, and outcomes of sepsis and urinary tract infection . Patients were recorded as developing sepsis if they required hospital admission for intravenous antibiotics. Fisher's exact test was employed for categorical variables, while the Student's <em>t</em> test was utilized for continuous variables for statistical significance.</div></div><div><h3>Results</h3><div>The rate of sepsis was 3.9% in the ciprofloxacin-only group, versus 0% in the ciprofloxacin plus gentamicin group (<em>P</em> value = 0.03). Overall aggregated post-TRUS infection rates was also 0% in the ciprofloxacin plus gentamicin group (<em>P</em> value = 0.005). We found no associated between infection and secondary risk factors.</div></div><div><h3>Conclusion</h3><div>The administration of 2 mg/kg intravenous gentamicin with oral ciprofloxacin prophylaxis reduces infection and sepsis rates post TRUS biopsy.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 90-95"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of transurethral resection of the prostate in benign prostatic hyperplasia patients with and without upper urinary tract dilatation: a propensity score matching analysis","authors":"Adem Utlu ,&nbsp;Tugay Aksakalli ,&nbsp;Isıl K. Aksakalli ,&nbsp;Ahmet E. Cinislioglu ,&nbsp;Ibrahim Karabulut","doi":"10.1016/j.prnil.2025.01.002","DOIUrl":"10.1016/j.prnil.2025.01.002","url":null,"abstract":"<div><h3>Background</h3><div>Upper urinary system dilation appears to be a precursor to the progression to renal failure as a result of benign prostatic hyperplasia (BPH). This study aimed to compare the outcomes of transurethral resection of the prostate (TUR-P) between BPH patients who develop upper urinary tract dilation (UUTD) and those in the normal group.</div></div><div><h3>Materials and methods</h3><div>Patients who underwent TUR-P for BPH diagnosis between 2019 and 2024 were included in the study. A propensity score matching was applied based on parameters such as age, International Prostate Symptom Score, prostate-specific antigen, prostate volume, serum creatinine, preoperative hemoglobin value, and presence of transurethral catheter. After the formation of the normal and UUTD patient groups, demographic and clinical data were compared. TUR-P outcomes, including International Prostate Symptom Score, clot retention, reoperation rates, blood transfusion rates, urinary retention rates, postoperative uroflow values, urodynamic requirements, and results were compared between the groups.</div></div><div><h3>Results</h3><div>After propensity score matching, a total of 128 patients who underwent TUR-P due to BPH, comprising 64 patients with UUTD and 64 patients with normal findings, were retrospectively reviewed. Mean hemoglobin level after TUR-P for UUTD group was 12.7 ± 1.9 g/dl, and for the normal group, it was 13.2 ± 2.1 g/dl. Postoperative clot retention rate UUTD and normal group was 4.7% and 3.1%, respectively. Blood transfusion rate for the UUTD group was 4.7%, and for the normal group, it was 1.6%. Postoperative urinary retention rate was higher in the UUTD group (18.7 vs. 9.4, <em>P</em> &lt; 0.05). Reoperation rate was 14% in the UUTD group and 7.8% in the normal group, with no statistically significant difference (<em>P</em> &gt; 0.05).</div></div><div><h3>Conclusions</h3><div>Although the rate of postoperative urinary retention is higher in patients with UUTD, which can lead to impaired kidney function during the course of BPH, TUR-P can be effectively performed without causing a significant increase in early or long-term complications.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 116-120"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the rarity: insights into primary diffuse large B-cell lymphoma of the prostate from a global retrospective analysis","authors":"Hejia Yuan ,&nbsp;Yongwei Li ,&nbsp;Jitao Wu ,&nbsp;Yining Zhao ,&nbsp;Fan Feng ,&nbsp;Hongwei Zhao ,&nbsp;Guohua Yu ,&nbsp;Peng Peng","doi":"10.1016/j.prnil.2024.11.008","DOIUrl":"10.1016/j.prnil.2024.11.008","url":null,"abstract":"<div><h3>Background</h3><div>The purpose of this study is to comprehensively analyze cases of primary diffuse large B-cell lymphoma of the prostate (P-DLBCL-P) from a global perspective, aiming to understand the disease's characteristics, treatment responses, and outcomes. By doing so, we seek to establish a valuable reference for the clinical management of this rare malignancy.</div></div><div><h3>Materials and methods</h3><div>This study conducted a retrospective review of P-DLBCL-P cases reported worldwide, using various online databases, including PubMed, Scopus, and other English databases, as well as WanFang Data and China National Knowledge Infrastructure in Chinese, collecting clinical pathology information, treatment modalities, and prognosis of patients, and conducted survival analysis using the Kaplan-Meier method.</div></div><div><h3>Results</h3><div>A cohort comprising 68 patients was enrolled in this study. Lower urinary tract symptoms were prevalent in 90.63% of cases. Furthermore, 89.5% of patients exhibited prostate-specific antigen levels below the threshold of 4 ng/mL. Prostate biopsy was the most commonly used method, accounting for 52.38% of cases, followed by transurethral resection of the prostate at 33.33%. Approximately 33.90% of patients diagnosed with prostate lymphoma experienced stage IV disease, with the bladder or ureter being the organs most frequently involved (53.33%). Surgical procedures were associated with an elevated risk of uncontrollable hemorrhage. Notably, chemotherapy demonstrated a positive therapeutic response, resulting in a complete remission rate of 50.94% and a partial remission rate of 28.30%. A subsequent follow-up study revealed a 1-year survival rate of 73.08% and a 3-year survival rate of 65.38%.</div></div><div><h3>Conclusions</h3><div>The symptoms of P-DLBCL-P are often atypical, leading to many patients being diagnosed at a later stage of the disease. Through a global study of cases, we have confirmed the efficacy of the rituximab–cyclophosphamide–adriamycin–vincristine–prednisone regimen as the preferred treatment option. Surgical intervention is typically only used for diagnostic purposes or to relieve organ obstruction.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 96-102"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel","authors":"Satı Coşkun Yazgan ,&nbsp;Abdulkadir Sarı ,&nbsp;Hatice Bölek ,&nbsp;Emre Yekedüz ,&nbsp;Yüksel Ürün","doi":"10.1016/j.prnil.2024.11.007","DOIUrl":"10.1016/j.prnil.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>To evaluate the prognostic value of the elimination rate constant K (KELIM), a marker of chemosensitivity, in mCRPC patients treated with docetaxel.</div></div><div><h3>Materials and methods</h3><div>The study included patients who had received first-line docetaxel for mCRPC. The KELIM score was calculated using PSA measurements obtained within the first 100 days of chemotherapy. The patients were divided into two groups based on the KELIM levels: KELIM PSA &lt;1 and KELIM PSA ≥1. The relationship between overall survival (OS) and the KELIM groups was evaluated.</div></div><div><h3>Results</h3><div>A total of 164 patients were included in this study. The median age was 68.1 years (interquartile range (IQR) 62.2-71.1). There were 76 and 88 patients in the KELIM PSA &lt;1 and KELIM PSA ≥1 groups, respectively. The median OS in the KELIM PSA ≥1 group (46.2 months, 95% confidence interval (CI): 38.8–53.6) was found to be longer than in the KELIM PSA &lt;1 group (32.0 months, 95% CI: 23.1–40.9) (<em>P</em> = 0.032). In multivariate analysis, the risk of death was independently higher in the KELIM PSA &lt;1 group than in the KELIM PSA ≥1 group (Hazard Ratio (HR): 1.58, 95% CI: 1.02-2.43, <em>P</em> = 0.037).</div></div><div><h3>Conclusions</h3><div>Higher KELIM scores are positively correlated with improved overall survival in mCRPC patients treated with docetaxel.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 103-106"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia","authors":"Teak Jun Shin ,&nbsp;Ji Yong Ha ,&nbsp;Se Yun Kwon ,&nbsp;Dong Jin Park ,&nbsp;Jang Hwan Kim ,&nbsp;Sung Won Lee ,&nbsp;In Gab Jeong ,&nbsp;Ji Youl Lee ,&nbsp;Tag Keun Yoo ,&nbsp;Tae Hyoung Kim ,&nbsp;Du Geon Moon ,&nbsp;Sung Kyu Hong ,&nbsp;Jin Seon Cho ,&nbsp;Hong Sang Moon ,&nbsp;Jeong Woo Lee ,&nbsp;Seok Joong Yun ,&nbsp;Youn Soo Jeon ,&nbsp;Jong Gwan Park ,&nbsp;Taek Won Kang ,&nbsp;Ki Hak Moon ,&nbsp;Kyung Seop Lee","doi":"10.1016/j.prnil.2024.10.001","DOIUrl":"10.1016/j.prnil.2024.10.001","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine and compare the efficacy and safety of GV1001 and 5 mg finasteride for benign prostatic hyperplasia (BPH) patients.</div></div><div><h3>Patients and methods</h3><div>This randomized, active-controlled, multicenter, phase 3 clinical trial enrolled 423 patients aged ≥50 years with a prostate volume (PV) &gt;30 mL. Patients were randomized into Group 1 (GV1001 0.56 mg + finasteride placebo), Group 2 (GV1001 1.12 mg + finasteride placebo), or Group 3 (GV1001 placebo +5 mg finasteride). The patients received the study drug during clinic visits every 2 weeks at weeks 0–22. Changes in the international prostate symptom score (IPSS), PV, maximum urinary flow rate (Qmax), prostate-specific antigen (PSA) level, residual urine volume, testosterone and dihydrotestosterone (DHT) levels, and international index of erectile function (IIEF) were assessed.</div></div><div><h3>Results</h3><div>We included 408 (96.45%) patients (Group 1, <em>n</em> = 138; Group 2, <em>n</em> = 134; Group 3, <em>n</em> = 136) in full analysis set for primary efficacy evaluations. All groups showed significant decreases and increases in the IPSS and Qmax, respectively (Groups 1, 2, and 3, IPSS: −4.78 ± 6.50, −4.99 ± 6.66, and −5.51 ± 6.42, respectively; <em>P</em> &lt; 0.0001; Qmax: <em>P</em> = 0.0005, <em>P</em> = 0.0039, and <em>P</em> &lt; 0.0001, respectively). PV reductions were observed in Groups 2 and 3 (−0.75 ± 8.21 mL [<em>P</em> = 0.3280] and −2.47 ± 7.92 mL [<em>P</em> = 0.0010], respectively). The PSA and testosterone levels of Group 3 significantly decreased and changed, respectively (−0.90 ± 1.25 ng/mL, <em>P</em> &lt; 0.0001 and <em>P</em> &lt; 0.0001, respectively). No significant differences were observed in the residual urine volume. DHT significantly decreased in all groups (Groups 1, 2, and 3: −71.41 ± 244.06 ng/mL [<em>P</em> = 0.0025], −73.84 ± 249.26 ng/mL [<em>P</em> = 0.0019], and −106.60 ± 178.29 ng/mL [<em>P</em> &lt; 0.0001], respectively). Only Group 3 exhibited a significantly decreased IIEF (−3.06 ± 15.34; <em>P</em> = 0.0323). Acute urinary retention occurred in one patient in Group 2. No patients underwent prostate surgery or minimally invasive procedures during the study.</div></div><div><h3>Conclusions</h3><div>GV1001 exhibited corresponding efficacy and tolerability, providing evidence of amelioration in urinary symptoms among patients with BPH in comparison to the use of 5 mg finasteride.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 81-89"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of robotics in the treatment of benign prostatic hyperplasia: a narrative review","authors":"Hyung Joon Kim ,&nbsp;Sung Kyu Hong","doi":"10.1016/j.prnil.2024.06.002","DOIUrl":"10.1016/j.prnil.2024.06.002","url":null,"abstract":"<div><div>A range of surgical approaches are available for treating benign prostatic hyperplasia (BPH), with emphasis placed not only on their effectiveness but also on minimizing invasiveness. The advent of surgical robotics has revolutionized BPH treatment, with robot-assisted simple prostatectomy offering a less invasive alternative to traditional approaches. The emergence of single-port systems has also earned attention for being effective in confined spaces. Aquablation represents a distinct robotic platform utilizing a heat-free, high-velocity waterjet to ablate prostate adenomas according to pre-registered configurations under real-time imaging. These novel technologies have proven to treat large prostates exceeding 80 mL efficiently and safely. Furthermore, Aquablation, along with technical modifications such as urethra-sparing robot-assisted simple prostatectomy, have demonstrated effectiveness in preserving ejaculatory function, thereby enhancing patients' overall quality of life. As evidence accumulates and technology and techniques evolve, robotic interventions for BPH may serve as a new standard in the field in the future.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 74-80"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141413657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data","authors":"Arya Bahadori ,&nbsp;Jessie Woods ,&nbsp;Lance Yuan ,&nbsp;Louise Emmett ,&nbsp;John Yaxley ,&nbsp;Matthew J. Roberts","doi":"10.1016/j.prnil.2025.03.003","DOIUrl":"10.1016/j.prnil.2025.03.003","url":null,"abstract":"<div><div>Prostate biopsy prior to radical treatment for prostate cancer is a common practice worldwide to allow diagnosis, prognostication, and treatment planning. However, recent advances in prostate multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) have made the possibility of a “biopsy-free” radical prostatectomy, without prior biopsy, closer to reality than before. The biopsy-free approach serves to avoid investigation-related morbidity, health care resources, and time to definitive treatment, but is not without risk. Here we review the literature surrounding the rationale, limitations, and current data.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 67-73"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of free PSA ratio to enhance detection of clinically significant prostate cancer in patients with PI-RADS<3 and PSA≤10","authors":"Ji Eun Heo,&nbsp;Hyun Ho Han,&nbsp;Won Sik Jang,&nbsp;Won Sik Ham,&nbsp;Woong Kyu Han,&nbsp;Young Deuk Choi,&nbsp;Jongsoo Lee","doi":"10.1016/j.prnil.2024.12.001","DOIUrl":"10.1016/j.prnil.2024.12.001","url":null,"abstract":"<div><h3>Background</h3><div>The necessity of prostate biopsy in patients with a Prostate Imaging–Reporting and Data System (PI-RADS) score below 3 and prostate-specific antigen (PSA) levels of 4–10 ng/ml remains controversial. We tested the diagnostic performance of the free PSA ratio (%fPSA) in detecting clinically significant cancer (CSC) in patients with PI-RADS &lt;3 and PSA ≤10 ng/ml.</div></div><div><h3>Methods</h3><div>We analyzed 1435 prostate biopsies performed by a single operator between April 2018 and January 2023 at a single institution. PSA and free PSA results on the day of biopsy or within 1 month were used, and all biopsies were performed after prostate magnetic resonance imaging (MRI). CSC was defined as Gleason grade group ≥2.</div></div><div><h3>Results</h3><div>Among 208 men with PI-RADS &lt;3 and PSA ≤10 ng/ml, CSC was detected in 37 (17.8%) patients. The median age was 65 years (interquartile range [IQR] 61–71), with a median PSA level of 5.06 ng/ml (IQR 3.98–7.08) and a median %fPSA of 18.2% (IQR 13.7–22.0). The area under the curve was 0.757 (95% confidence interval, 0.674–0.841), with a %fPSA cutoff of 17.6%, sensitivity of 86.5%, specificity of 63.7%, positive likelihood ratio (LR) of 2.38, and negative LR of 0.21. CSC was diagnosed in 5 out of 114 patients (4%) with %fPSA &gt;17.6%, compared to 32 out of 94 patients (34%) with %fPSA &lt;17.6%.</div></div><div><h3>Conclusions</h3><div>In patients with PI-RADS &lt;3 and PSA ≤10 ng/ml, %fPSA values &lt; 17.6% may facilitate early prostate cancer diagnosis in those who might not undergo biopsy based on MRI results alone. Additionally, unnecessary biopsies could be avoided in patients with elevated PSA levels when %fPSA exceeds 17.6%.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 112-115"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use versus nonuse of antimicrobial prophylaxis prior to transperineal prostate biopsy: a propensity score-matched analysis","authors":"Dong Sup Lee,&nbsp;Seung-Ju Lee,&nbsp;Su Jin Kim,&nbsp;Je Mo Yoo,&nbsp;Young Hyo Choi,&nbsp;Hee Youn Kim","doi":"10.1016/j.prnil.2024.12.002","DOIUrl":"10.1016/j.prnil.2024.12.002","url":null,"abstract":"<div><h3>Background</h3><div>Transperineal prostate biopsy offers advantage over a transrectal approach by reducing the risk of infectious complications. However, the necessity for antimicrobial prophylaxis (AP) before a transperineal prostate biopsy is less clear. This study aimed to study the rate of infectious complications following transperineal prostate biopsy with or without AP.</div></div><div><h3>Materials and methods</h3><div>Propensity score matching was done for 1,273 patients who underwent transperineal prostate biopsy between October 2020 and October 2024 to adjust for differences in covariates. Parameters including the rate of urinary tract infection (UTI) requiring or not requiring hospitalization between patients who received AP and those who did not receive AP were then compared.</div></div><div><h3>Results</h3><div>A total of 288 patients were matched for each group and baseline characteristics were balanced between groups. The overall incidence of UTI was very low in both groups without significant difference. UTI requiring hospitalization occurred in only one patient in the AP group (0.1%) and none in the non-AP group. Nonhospitalized UTI occurred in 0.7% of the AP group and 0.3% of the non-AP group (<em>P</em> = 1.000).</div></div><div><h3>Conclusion</h3><div>There was no significant difference in the rate of UTI based on the use or nonuse of AP prior to transperineal prostate biopsy. The overall incidence of UTI was very low regardless of the use of AP. Omission of AP prior to transperineal prostate biopsy might be possible, which would help promote antimicrobial stewardship.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 107-111"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of surgical outcomes between outpatient and inpatient robot-assisted radical prostatectomy: A systematic review and meta-analysis","authors":"Tuan T. Nguyen ,&nbsp;Muhammed A. Moukhtar Hammad ,&nbsp;Ryan W. Dobbs ,&nbsp;Huy G. Vuong ,&nbsp;Jacob Basilius ,&nbsp;Khoa Quy ,&nbsp;Hanh T.T. Ngo ,&nbsp;An Nguyen ,&nbsp;Thi Tuyet Mai Tran ,&nbsp;Narmina Khanmammadova ,&nbsp;Trinh N.K. Van ,&nbsp;Sohrab N. Ali ,&nbsp;Ho Yee Tiong ,&nbsp;Se Young Choi ,&nbsp;Mohammed Shahait ,&nbsp;David I. Lee","doi":"10.1016/j.prnil.2024.04.003","DOIUrl":"10.1016/j.prnil.2024.04.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Several institutions have reported their experience with outpatient robot-assisted radical prostatectomy (O-RARP). However, it is unclear if the utilization of this approach represents an improvement over inpatient robot-assisted radical prostatectomy (I-RARP). This meta-analysis sought to compare the surgical outcomes between O-RARP and I-RARP.</div></div><div><h3>Methods</h3><div>For relevant articles, three electronic databases, including PubMed, Scopus, and Web of Science, were searched from their inception until April 30, 2022. A meta-analysis has been reported in line with PRISMA 2020 and AMSTAR guidelines. The risk ratio (RR) and weighted mean difference (MD) were applied for the comparison of dichotomous and continuous variables with 95% confidence intervals (CI).</div></div><div><h3>Results</h3><div>of the 297 retrieved abstracts, 12 underwent full-text review, and 11 studies were included in the final analysis, comprising a total cohort of 2,875 cases of robot-assisted radical prostatectomy (892 O-RARP cases and 1,983 I-RARP cases). Compared to I-RARP, the O-RARP group had lower mean operative time (MD = −9.4 minutes, 95% CI −15.1 to −3.7, <em>P</em> = 0.001), fewer overall postoperative complications (RR = 0.65, 95% CI 0.46 to 0.92, <em>P</em> = 0.017), shorter hospital stay (MD = −22.9 hours, 95% CI −26.0 to −19.7, <em>P</em> ≤ 0.001), and lower postoperative opioid requirements (RR = 0.45, 95% CI 0.28 to 0.71, <em>P</em> = 0.001). There were no significant differences in other outcomes, including: estimated blood loss, postoperative pain score, unscheduled visits after surgery, positive surgical margins, biochemical recurrence, International Prostate Symptom Score (IPSS) after surgery, or three- and six-month continence rates.</div></div><div><h3>Conclusions</h3><div>This meta-analysis demonstrates that O-RARP is a safe and feasible option for patients undergoing surgery for localized prostate cancer. Further studies are needed to better evaluate optimal patient selection, associated healthcare costs, and patient-reported outcomes.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 1","pages":"Pages 1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}